LFVN: LifeVantage Corporation Stock

by  •  • Comments Off on LFVN: LifeVantage Corporation Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 112.59
Enterprise Value ($M) 95.70
Book Value ($M) 25.99
Book Value / Share 2.08
Price / Book 4.33
NCAV ($M) 3.34
NCAV / Share 0.27
Price / NCAV 33.73

Profitability (mra)
Return on Invested Capital (ROIC) 0.07
Return on Assets (ROA) 0.04
Return on Equity (ROE) 0.08

Liquidity (mrq)
Quick Ratio 1.01
Current Ratio 1.69

Balance Sheet (mrq) ($M)
Current Assets 37.65
Assets 60.30
Liabilities 34.31
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 200.16
Operating Income 4.33
Net Income 2.94
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 12.20
Cash from Investing -2.25
Cash from Financing -14.42

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
07-31 13D/A Radoff Bradley Louis 4.99 -26.39
02-15 13D/A Sudbury Capital Management, LLC 5.90 0.00
02-13 13G/A Renaissance Technologies Llc 6.51 -2.40
2023-08-11 13D/A Sudbury Capital Fund, LP 5.80 16.05

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-08-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K
2024-05-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-01-30 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SE
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-09-06 72,072 312,823 23.04
2024-09-05 16,403 100,882 16.26
2024-09-04 34,491 92,885 37.13
2024-09-03 25,687 103,575 24.80

(click for more detail)

Similar Companies
KTTA – Pasithea Therapeutics Corp. KZR – Kezar Life Sciences, Inc.
LEXX – Lexaria Bioscience Corp. LGVN – Longeveron Inc.
LIPO – Lipella Pharmaceuticals Inc.


Financial data and stock pages provided by
Fintel.io